TEM

Tempus AI Inc Class A Common Stock (TEM) | Rumor.io

Tempus AI

TEM

Attention (50-day avg)0.03%

Attention rank (50-day avg)#228

Bullish sentiment (50-day avg)97%

Price to earnings ratio39.3

Market capitalization15.4B

Earnings per share-1.44

Dividend yield (TTM)—

Revenue (annual)1.3B

Net income (annual)-245M

Social

What share of all stock conversation is about TEM?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% -0.11	0.03% -0.11	0.04% +0.02	0.07% -0.1

Sep 29

Tempus AI, Inc. ($TEM) has reported a 6-month net loss of $120M, a $107M stock comp expense, and a $2.5B accumulated deficit.
Despite a $5.6M GAAP Q2 profit, Tempus AI's valuation leaves little margin, with $8M adjusted EBITDA on $382M Q2 revenue.
The company's $120M 6-month net loss and $107M stock comp expense are raising concerns among investors, with some speculating about a potential bankruptcy.

Generated by AI

Sentiment

Of the messages about TEM that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	83.33% -15.82	96.65% -1.21	96.19% -1.34	98.61% +5.62
Bearish	16.67% +15.82	3.35% +1.21	3.81% +1.34	1.39% -5.62

Bullish· Sep 25

$TEM is breaking out with a clear bullish trend, with the stock price expected to reach $87.50.
Tempus AI's stock is experiencing strong buying action, and the company is well-positioned to capitalize on the growing importance of AI in the healthcare industry.
The stock has the potential to 10X in 10 years, driven by its expected growth in revenue and earnings, with a strong consensus estimate for the current year's earnings improvement.

Bearish· Sep 17

The company's insiders have been selling shares, which may indicate a lack of confidence in the stock's future performance.
The stock has been unable to break through a key resistance level at $81.28, and may continue to experience selling pressure.
There is a significant short interest in the stock, which could potentially lead to a sharp decline if the shorts are forced to cover their positions.

Generated by AI

Topics

Of the messages about TEM that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Technical Analysis	100%	2.62%	3.3%	0.99%
Announcements	0%	0.63%	0.1%	1.07%
Analysts	0%	12.13%	46.67%	48.46%
Earnings	0%	0%	0%	1%
Macro	0%	84.62%	49.94%	48.48%
Controversies	0%	0%	0%	0%

Earnings· May 5

Tempus AI, Inc. ($TEM) reported Q1 2026 earnings, beating EPS estimates by 45.8% and revenue estimates by 0.75%.
The company's revenue rose 36.1% to $348.1M, driven by growth in its diagnostics and AI-driven data business, with diagnostics revenue increasing 34.7% year-over-year.
Tempus AI raised its full-year 2026 revenue guidance to approximately $1.59-$1.6 billion, driven by strong growth in its diagnostics and AI-driven data business.

Analysts· Feb 25

JPMorgan downgraded Tempus AI (TEM) to Neutral from Overweight with a price target of $55, citing valuation concerns after a 106% YTD stock run-up.
Loop Capital raised the price target on Tempus AI to $74 from $52, maintaining a Buy rating and citing the company's consistent Q4 results and its position as a long-term beneficiary of precision medicine trends.
Stifel analysts maintained a Hold rating on Tempus AI with a price target of $65, citing the company's Q4 results and its guidance, but noting that the stock's valuation may be fully priced after the recent rally.

Announcements· Jun 5

The Trump administration has expressed interest in taking voluntary equity stakes in major AI companies, with Sam Altman reportedly pitching the idea directly to Trump.
Tempus AI, Inc. ($TEM) has been quietly building momentum and is now breaking out of a wedge pattern, with some analysts predicting a potential +46% move if it reaches January highs.
Gilead has expanded its deal with Tempus AI for enterprise-wide access to AI tools and real-world oncology data, highlighting the company's growing presence in the AI and healthcare sectors.

Macro· May 15

Brazil's high interest rates are due to the government's continuous overspending, which exceeds revenue.
To prevent inflation from worsening, the central bank must raise interest rates.
Tempus AI, Inc.'s (TEM) shares may be impacted by monetary policy decisions affecting Brazil's economy.

Technical Analysis· Sep 22

Tempus AI, Inc. ($TEM) is experiencing a significant price surge after FDA approval of its Tempus Pixel Cardiac Imaging Platform.
The stock has been in a strong uptrend, with a recent earnings report showing 89.6% YoY revenue growth and a raised full-year 2025 revenue guidance.
Technical analysis suggests a potential retest of resistance near $80, with a possible rangebound breakout, and a key support level at $70.

Generated by AI

Community

Of the messages about TEM, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	54.55%	50.87%	22.42%	18.09%
Newcomers	45.45%	49.13%	77.58%	81.91%

Regulars· Sep 25

Tempus AI, Inc. ($TEM) is poised to capitalize on the growing impact of AI advancements on the healthcare industry, with some regulars expecting a 10X return in 10 years.
Strong buying action is observed in $TEM, with some analysts expecting a move towards $87 and $92 based on technical indicators.
High-risk, high-reward strategies may be applied to $TEM, with some investors aiming to capture significant gains by buying into intense pain and limiting chasing.

Newcomers· Sep 18

Newcomers are focused on the potential for a short squeeze due to improving fundamentals in the business, with some predicting a strong close above $80.
Some users are taking profits and expecting a retrace to $69, while others are buying the dip and expecting a continued upward trend.
The stock has been trending upward throughout the day, with a +14.8% gain at the bell, suggesting strong buying interest and a bullish outlook.

Generated by AI

News

Personalis: The Wrong Side Of The Merger (NASDAQ:PSNL)

Personalis shareholders remain exposed to downside in TEM shares while having limited ability to benefit from further TEM appreciation above $48.42. Learn more about PSNL stock here.

2h agoSeeking Alpha

Tempus AI receives FDA clearance for heart valve AI tool

1d agoInvesting.com

Cathie Wood's Ark Invest weekly recap: boosts Meta, Rocket Lab; cuts Tempus AI, CrowdStrike (ARKK:BATS)

Cathie Wood’s Ark Invest boosted its technology, biotechnology, and space exposure last week, led by purchases of more than 51K shares of Meta Platforms (META) worth $38.2M and roughly 360K shares of Rocket Lab (RKLB) worth $25.9M.

2d agoSeeking Alpha

Also Discussed

Investors talking about TEM also mention

#	Name	Attention
1	Personalis Inc.PSNL	0%-0.01
2	Recursion Pharmaceuticals, Inc. Class A Common StockRXRX	0.01%+0
3	Vistra CorpVST	0.1%-0.39
4	Oscar Health, Inc.OSCR	0.05%+0.02
5	Astera Labs, Inc.ALAB	0.05%+0.03
6	Rigetti Computing, Inc.RGTI	0.01%-0.01
7	Gyre Therapeutics Inc.GYRE	0%0
8	IonQ, Inc.IONQ	0.11%-0.08
9	Oklo Inc.OKLO	0.01%-0.08
10	Zeta Global Holdings Corp.ZETA	0%-0.03

Tempus AI Inc Class A Common Stock

Healthcare
Health Information Services

Tempus AI Inc Class A Common Stock is the equity of Tempus AI, a healthcare technology company focused on applying artificial intelligence and machine learning to precision medicine. The company develops AI-enabled solutions that help physicians use clinical and molecular data to support more personalized care, while also providing tools and services that assist life-sciences customers with research, diagnostics, and therapeutic development. Its current business is organized around genomics, data, and artificial intelligence applications, with products spanning next-generation sequencing, molecular profiling, clinical decision support, and software-based diagnostic tools. Tempus AI serves healthcare providers, researchers, and pharmaceutical and biotechnology companies across oncology and other clinical areas, including cardiology, neuropsychiatry, infectious disease, and radiology. The stock represents ownership in a company positioned at the intersection of healthcare, data analytics, and diagnostic innovation.

Website

Location

600 West Chicago Avenue

Chicago, IL, 60654

United States

Social

What share of all stock conversation is about TEM?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% -0.11	0.03% -0.11	0.04% +0.02	0.07% -0.1

Sep 29

Tempus AI, Inc. ($TEM) has reported a 6-month net loss of $120M, a $107M stock comp expense, and a $2.5B accumulated deficit.
Despite a $5.6M GAAP Q2 profit, Tempus AI's valuation leaves little margin, with $8M adjusted EBITDA on $382M Q2 revenue.
The company's $120M 6-month net loss and $107M stock comp expense are raising concerns among investors, with some speculating about a potential bankruptcy.

Generated by AI

Sentiment

Of the messages about TEM that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	83.33% -15.82	96.65% -1.21	96.19% -1.34	98.61% +5.62
Bearish	16.67% +15.82	3.35% +1.21	3.81% +1.34	1.39% -5.62

Bullish· Sep 25

$TEM is breaking out with a clear bullish trend, with the stock price expected to reach $87.50.
Tempus AI's stock is experiencing strong buying action, and the company is well-positioned to capitalize on the growing importance of AI in the healthcare industry.
The stock has the potential to 10X in 10 years, driven by its expected growth in revenue and earnings, with a strong consensus estimate for the current year's earnings improvement.

Bearish· Sep 17

The company's insiders have been selling shares, which may indicate a lack of confidence in the stock's future performance.
The stock has been unable to break through a key resistance level at $81.28, and may continue to experience selling pressure.
There is a significant short interest in the stock, which could potentially lead to a sharp decline if the shorts are forced to cover their positions.

Generated by AI

Topics

Of the messages about TEM that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Technical Analysis	100%	2.62%	3.3%	0.99%
Announcements	0%	0.63%	0.1%	1.07%
Analysts	0%	12.13%	46.67%	48.46%
Earnings	0%	0%	0%	1%
Macro	0%	84.62%	49.94%	48.48%
Controversies	0%	0%	0%	0%

Earnings· May 5

Tempus AI, Inc. ($TEM) reported Q1 2026 earnings, beating EPS estimates by 45.8% and revenue estimates by 0.75%.
The company's revenue rose 36.1% to $348.1M, driven by growth in its diagnostics and AI-driven data business, with diagnostics revenue increasing 34.7% year-over-year.
Tempus AI raised its full-year 2026 revenue guidance to approximately $1.59-$1.6 billion, driven by strong growth in its diagnostics and AI-driven data business.

Analysts· Feb 25

JPMorgan downgraded Tempus AI (TEM) to Neutral from Overweight with a price target of $55, citing valuation concerns after a 106% YTD stock run-up.
Loop Capital raised the price target on Tempus AI to $74 from $52, maintaining a Buy rating and citing the company's consistent Q4 results and its position as a long-term beneficiary of precision medicine trends.
Stifel analysts maintained a Hold rating on Tempus AI with a price target of $65, citing the company's Q4 results and its guidance, but noting that the stock's valuation may be fully priced after the recent rally.

Announcements· Jun 5

The Trump administration has expressed interest in taking voluntary equity stakes in major AI companies, with Sam Altman reportedly pitching the idea directly to Trump.
Tempus AI, Inc. ($TEM) has been quietly building momentum and is now breaking out of a wedge pattern, with some analysts predicting a potential +46% move if it reaches January highs.
Gilead has expanded its deal with Tempus AI for enterprise-wide access to AI tools and real-world oncology data, highlighting the company's growing presence in the AI and healthcare sectors.

Macro· May 15

Brazil's high interest rates are due to the government's continuous overspending, which exceeds revenue.
To prevent inflation from worsening, the central bank must raise interest rates.
Tempus AI, Inc.'s (TEM) shares may be impacted by monetary policy decisions affecting Brazil's economy.

Technical Analysis· Sep 22

Tempus AI, Inc. ($TEM) is experiencing a significant price surge after FDA approval of its Tempus Pixel Cardiac Imaging Platform.
The stock has been in a strong uptrend, with a recent earnings report showing 89.6% YoY revenue growth and a raised full-year 2025 revenue guidance.
Technical analysis suggests a potential retest of resistance near $80, with a possible rangebound breakout, and a key support level at $70.

Generated by AI

Community

Of the messages about TEM, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	54.55%	50.87%	22.42%	18.09%
Newcomers	45.45%	49.13%	77.58%	81.91%

Regulars· Sep 25

Tempus AI, Inc. ($TEM) is poised to capitalize on the growing impact of AI advancements on the healthcare industry, with some regulars expecting a 10X return in 10 years.
Strong buying action is observed in $TEM, with some analysts expecting a move towards $87 and $92 based on technical indicators.
High-risk, high-reward strategies may be applied to $TEM, with some investors aiming to capture significant gains by buying into intense pain and limiting chasing.

Newcomers· Sep 18

Newcomers are focused on the potential for a short squeeze due to improving fundamentals in the business, with some predicting a strong close above $80.
Some users are taking profits and expecting a retrace to $69, while others are buying the dip and expecting a continued upward trend.
The stock has been trending upward throughout the day, with a +14.8% gain at the bell, suggesting strong buying interest and a bullish outlook.

Generated by AI

Tempus AI

Social

Sep 29

Bullish· Sep 25

Bearish· Sep 17

Earnings· May 5

Analysts· Feb 25

Announcements· Jun 5

Macro· May 15

Technical Analysis· Sep 22

Regulars· Sep 25

Newcomers· Sep 18

Personalis: The Wrong Side Of The Merger (NASDAQ:PSNL)

Tempus AI receives FDA clearance for heart valve AI tool

Cathie Wood's Ark Invest weekly recap: boosts Meta, Rocket Lab; cuts Tempus AI, CrowdStrike (ARKK:BATS)

Tempus AI CEO Lefkofsky sells $16.1m common stock

Tempus AI CEO Ryan Fukushima sells $49,000 in stock

Tempus AI CAO Ryan Bartolucci sells $529,650 in stock

Also Discussed

Tempus AI Inc Class A Common Stock

Company Information

Location

Personalis: The Wrong Side Of The Merger (NASDAQ:PSNL)

Tempus AI receives FDA clearance for heart valve AI tool

Cathie Wood's Ark Invest weekly recap: boosts Meta, Rocket Lab; cuts Tempus AI, CrowdStrike (ARKK:BATS)

Tempus AI CEO Lefkofsky sells $16.1m common stock

Tempus AI CEO Ryan Fukushima sells $49,000 in stock

Tempus AI CAO Ryan Bartolucci sells $529,650 in stock

Also Discussed

Social

Sep 29

Bullish· Sep 25

Bearish· Sep 17

Earnings· May 5

Analysts· Feb 25

Announcements· Jun 5

Macro· May 15

Technical Analysis· Sep 22

Regulars· Sep 25

Newcomers· Sep 18